Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 9/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 8/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 7/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 2/20 | 0.37 |
| ▸ | GUSB | P08236 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309903 | 1.00 | NOD2 (0.39) | NOD2RIPK2ACVR1HTR6IGF1R | |
| SCHEMBL29567259 | 0.92 | HTR6 (0.39) | NOD2RIPK2ACVR1HTR6IGF1R | |
| SCHEMBL26808704 | 0.92 | RAD52 (0.39) | IGF1REGFRJAK3TNK2MAPT | |
| SCHEMBL24309725 | 0.92 | HTR6 (0.39) | NOD2RIPK2ACVR1HTR6IGF1R | |
| SCHEMBL29567089 | 0.90 | HTR6 (0.37) | NOD2RIPK2ACVR1HTR6IGF1R | |
| SCHEMBL24310067 | 0.90 | HTR6 (0.37) | NOD2RIPK2ACVR1HTR6IGF1R | |
| SCHEMBL24309384 | 0.88 | HTR1A (0.39) | EGFRSMN1; SMN2 | |
| SCHEMBL29566871 | 0.88 | HTR1A (0.39) | EGFRSMN1; SMN2 | |
| SCHEMBL26808712 | 0.85 | HTR7 (0.41) | HTR6IGF1RGUSBEGFRJAK3 | |
| SCHEMBL24310024 | 0.84 | LCK (0.36) | NOD2RIPK2ACVR1HTR6GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-4225748-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | NOD2 724/4885RIPK2 3698/4885ACVR1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.